AKT3 and hepatocellular carcinoma: In addition, the miR-217/AKT3 axis is dysregulated in TC and NSCLC [61,92,94]; the miR-424-5p/AKT3 axis is dysregulated in HCC, NPC, endometrial adenocarcinoma, and glioma [70,88,95,99]; the miR-489/AKT3 axis is dysregulated in drug-resistant BC, cisplatin-resistant OC cells, and PC [57,82,84]; and the miR-610/AKT3 axis is dysregulated in GBM and MM [98,102,103].